Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Director Sells $2,890,000.00 in Stock
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Director Michael S. Perry sold 100,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, September 9th. The shares were sold at an average price of $28.90, for a total transaction of $2,890,000.00. Following the completion of the transaction, the director now owns 121,000 shares in the company, valued at $3,496,900. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
ARWR traded up $2.17 on Wednesday, reaching $30.89. The company’s stock had a trading volume of 1,814,086 shares, compared to its average volume of 1,726,114. Arrowhead Pharmaceuticals Inc has a 1 year low of $10.41 and a 1 year high of $36.80. The stock has a market cap of $2.72 billion, a price-to-earnings ratio of -47.52 and a beta of 1.51. The business’s 50 day moving average is $30.86 and its 200 day moving average is $24.20.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, August 5th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.34 by ($0.13). The business had revenue of $42.70 million for the quarter, compared to the consensus estimate of $59.05 million. Arrowhead Pharmaceuticals had a net margin of 33.28% and a return on equity of 26.27%. Research analysts anticipate that Arrowhead Pharmaceuticals Inc will post 0.73 earnings per share for the current year.
A number of equities research analysts have commented on the company. BidaskClub downgraded Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Cantor Fitzgerald cut Arrowhead Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $24.00 price target on the stock. in a report on Thursday, June 27th. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 1st. B. Riley upped their price objective on Arrowhead Pharmaceuticals from $32.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Finally, Piper Jaffray Companies lifted their target price on shares of Arrowhead Pharmaceuticals from $33.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $33.70.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Recommended Story: How to use beta for portfolio diversification
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.